论文部分内容阅读
CXCL12是趋化因子家族成员之一,是能够特异性结合其受体CXCR4发挥趋化性作用的细胞因子。最初,CXCL12及CXCR4被发现于炎症细胞,参与机体炎症、免疫等病理反应。接下来的几年中发现,它在机体发育、成熟过程中也有重要作用。如今,大量研究表明它与肿瘤的生长、侵袭及转移密切相关。据报道,在乳腺癌、肺癌、卵巢癌等二十余种肿瘤组织中发现CXCL12及CXCR4的表达,其中也包括中枢系统肿瘤-胶质瘤。CXCL12/CXCR4参与胶质瘤生长过程的多个步骤,包括肿瘤增殖、侵袭、转移等。有实验指出,转移灶的CXCR4表达水平较原发灶高,CXCR4有可能成为抑制胶质瘤生长、转移的重要靶目标。
CXCL12, a member of the chemokine family, is a cytokine that specifically binds to its receptor, CXCR4, for chemotaxis. Initially, CXCL12 and CXCR4 were found in inflammatory cells, involved in the body inflammation, immune and other pathological reactions. The next few years found that it also plays an important role in the development and maturation of the body. Now, a large number of studies show that it is closely related to tumor growth, invasion and metastasis. It is reported that in breast cancer, lung cancer, ovarian cancer more than twenty kinds of tumor tissues found CXCL12 and CXCR4 expression, which also includes the central system tumor - glioma. CXCL12 / CXCR4 involved in glioma growth process of multiple steps, including tumor proliferation, invasion, metastasis and so on. Some experiments pointed out that the expression of CXCR4 in metastasis is higher than that in primary tumor, and CXCR4 may be an important target for inhibiting the growth and metastasis of glioma.